MVMichal Vieth

Michal Vieth

*This is an algorithmically generated author record based on publicly available information.

Michal Vieth has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Cen Gao

    Discovery chemistry, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Discovery Chemistry Research and Technologies, DC 1931, Indianapolis, Indiana, 46285

    2 shared publications
  • Cen Gao

    1 shared publication
  • Christos A. Nicolaou

    Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

    1 shared publication
  • David J. Cummins

    Discovery Chemistry, ‡Discovery Statistics, §Advanced Analytics, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

    1 shared publication
  • Ian A. Watson

    Discovery Chemistry, ‡Discovery Statistics, §Advanced Analytics, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States

    1 shared publication
  • Ian James Watson

    University of Seoul

    1 shared publication

Latest Publications

  • Are induced fit protein conformational changes caused by ligand‐binding predictable? A molecular dynamics investigation

    by Cen Gao, Jeremy Desaphy, Michal Vieth

    In this work, the ability of molecular dynamics simulations (MD) to prospectively predict regions of ligand binding sites that could undergo induced fit effects was investigated. Conventional MD was run on 39 apo structures (no ligand), and the resulting trajectories were compared to a set of 147 holo X‐ray structures (ligand‐bound). It was observed from the simulations, in the absence of the ligands, that structures exhibiting large residue conformational changes indicated higher likelihood of induced fit effects. Nevertheless, the simulation results did not perform better than using the normalized crystallographic structural factors as predictors of active‐site rigid residues (87% predictive power) and mobile residues (47% predictive power). While the simulations could not produce full active sites conformations similar to holo‐like states, it was found that the simulations could reproduce bound state conformations of individual residues. These results suggest potential issues in the use of unligated simulation frames directly for drug design applications such as ligand docking, and an overall caution in the use of protein flexibility in docking protocols should be emphasized.


  • Knowledge-Based Strategy to Improve Ligand Pose Prediction Accuracy for Lead Optimization

    by Cen Gao, Nels Thorsteinson, Ian Watson, Jibo Wang, Michal Vieth

    Accurately predicting how a small molecule binds to its target protein is an essential requirement for structure-based drug design (SBDD) efforts. In structurally enabled medicinal chemistry programs, binding pose prediction is often applied to ligands after a related compound’s crystal structure bound to the target protein has been solved. In this article, we present an automated pose prediction protocol that makes extensive use of existing X-ray ligand information. It uses spatial restraints during docking based on maximum common substructure (MCS) overlap between candidate molecule and existing X-ray coordinates of the related compound. For a validation data set of 8784 docking runs, our protocol’s pose prediction accuracy (80–82%) is almost two times higher than that of one unbiased docking method software (43%). To demonstrate the utility of this protocol in a project setting, we show its application in a chronological manner for a number of internal drug discovery efforts. The accuracy and applicability of this algorithm (>70% of cases) to medicinal chemistry efforts make this the approach of choice for pose prediction in lead optimization programs.


  • Selectivity Data: Assessment, Predictions, Concordance, and Implications

    by Cen Gao, Suntara Cahya, Christos A. Nicolaou, Jibo Wang, Ian A. Watson, David J. Cummins, Philip W. Iversen, Michal Vieth

    Could high-quality in silico predictions in drug discovery eventually replace part or most of experimental testing? To evaluate the agreement of selectivity data from different experimental or predictive sources, we introduce the new metric concordance minimum significant ratio (cMSR). Empowered by cMSR, we find the overall level of agreement between predicted and experimental data to be comparable to that found between experimental results from different sources. However, for molecules that are either highly selective or potent, the concordance between different experimental sources is significantly higher than the concordance between experimental and predicted values. We also show that computational models built from one data set are less predictive for other data sources and highlight the importance of bias correction for assessing selectivity data. Finally, we show that small-molecule target space relationships derived from different data sources and predictive models share overall similarity but can significantly differ in details.